EFRO grant for drug development against vector-borne infections
A Nijmegen-based public-private partnership received 1.5 million Euro from the European Fund for Regional Development (EFRO). With this grant, the consortium aims to develop novel therapeutics against mosquito-transmitted tropical infectious diseases, such as Malaria, dengue virus and Zika virus. The consortium consists of the spinoff companies Protinhi Therapeutics, TropIQ Health Sciences, both based at the Novio Tech Campus, and scientists from Radboud University (dr. Martin Feiters, prof. Floris Rutjes) and Radboud University Medical Center, dept. Medical Microbiology (dr. Ronald van Rij, prof. Robert Sauerwein).